Meeting Report

Neratinib for Extended Anti-HER2 Therapy in Early Breast Cancer

Presented by G. Thomas Budd,(1) MD, and Wendy H. Vogel,(2) MSN, FNP, AOCNP®

1)Taussig Cancer Center at Cleveland Clinic, Cleveland, Ohio; 2)Wellmont Cancer Institute, Kingsport, Tennessee

Presenters’ disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2018;9(3):298–302 | https://doi.org/10.6004/jadpro.2018.9.3.5 | © 2018 Harborside™


  

ABSTRACT

Neratinib following the completion of trastuzumab has been shown to reduce the risk of disease recurrence for patients with HER2-positive early breast cancer in whom extended adjuvant therapy seems advisable. In clinical trials, the most common side effect of neratinib and other anti-HER2 therapies was diarrhea. Presenters at JADPRO Live clarified the findings of trials studying the benefit of differing prophylactic regimens with loperamide, budesonide, and colestipol.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.